At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 341 enrolled
Drug / intervention
Esomeprazoledrug
Likely dose
Esomeprazole 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Esomeprazole 20 mg Once Daily in Subjects With Frequent Heartburn
In Brief
A Phase 3 clinical trial evaluating Esomeprazole for Heartburn. Completed, enrolled 341 participants across 10 sites.
Detailed Summary
This study will investigate the efficacy of esomeprazole 20 mg once a day in the treatment of frequent heartburn
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeartburn
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartAug 2011
Primary CompletionOct 2011
TodayJul 2026
First PostedJun 10, 2011
Enrollment StartAug 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.1 years ago
Interventions
Esomeprazoledrug
Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose